

Formulary Update

March 2024

The following changes to the [Adult Medicines Formulary](#) have been agreed during the ADTC or sub-committee meetings since January 2024. Additions and deletions of medicines are based on submitted formulary appeals, new drug assessment requests or formulary section reviews. Changes in preferred brands are based on decisions by Prescribing Management Groups.

ADTC decisions relating to SMC assessments are published in alternate months and can be accessed [here](#)

Deletions	Indication	Adult Medicines Formulary entry/ rationale	
Capsaicin cream		10.3.2	Discontinued
Crianlizumab		9.1.3	Discontinued
Diflucortolone		13.4.9	Discontinued
Lixisenatide		6.1.2.6	Discontinued
Michol		11.8.2	Discontinued
Mobocertinib		8.1.5	Marketing authorisation in UK withdrawn
Ocriplasmin		11.8.2	Discontinued
Pregaday		9.1.1.1	Discontinued

Additions	Indication	Adult Medicines Formulary entry/ rationale	
Metformin MR	Diabetes	6.1.2.2	Formulary appeal
Yacella®	Contraception	7.3.1.2	Primary care guideline and formulary section review

Changes in preferred medicines or brand	New preferred medicines or brand	Adult Medicines Formulary entry / rationale	
Apixaban	Preferred DOAC for atrial fibrillation (replacing edoxaban)	2.8.2	MCEG cost-efficiency project
Beclomethasone+ formoterol inhaler	Luforbec® now preferred aerosol inhaler brand	3.2.2	MCEG cost-efficiency project
Estriol cream 0.1%	Brand name Ovestin removed	7.2.1	Company debranded their product
Fluoroquinolones	SPAG statement added regarding cautions for use	5.1.12	
Pivmecillinam	Formulary Prescribing Notes updated	5.1.1.5	Antimicrobial utilisation subcommittee advice
Sitagliptin	Preferred DPP4 inhibitor, if indicated (replacing alogliptin)	6.1.2.4	MCEG cost-efficiency project
Tacrolimus	Highlighted that Adoport now preferred brand for liver and renal transplant patients	8.2.2	Local specialist service decision

Tiotropium inhaler	Tiogiva® preferred brand for DPIs	3.1.2	MCEG cost-efficiency project
--------------------	-----------------------------------	-------	------------------------------

Other changes	Changes made	Adult Medicines Formulary entry/ rationale	
Desogestrel	Removal of restriction to 2 nd line treatment option	7.3.2.1	Primary care guideline and formulary section review
Progesterone micronized	Brand name removed	6.4.1.2	Multiple preparations now on the market